The American Society for Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) have issued guidance on the use of definitive local therapy to treat patients with oligometastatic non-small cell lung cancer (NSCLC).
"Oligometastatic NSCLC is a phase in lung cancer development that may offer us new opportunities to improve patient outcomes because it typically is more treatable than widely metastatic cancer," said Dr. Puneeth Iyengar, PhD, a radiation oncologist at the University of Texas Southwestern Medical Center and co-chair of the guideline task force, in a news release from ASTRO. The guideline was published April 25 in Practical Radiation Oncology.
The guideline addresses key questions focused on the use of local (radiation, surgery, other ablative methods) and systemic therapy in the management of oligometastatic NSCLC.
Specifically, the questions address identification of evidence-based clinical scenarios for using local therapy, sequencing, and timing when integrating local with systemic therapies, radiation techniques critical for oligometastatic disease targeting and treatment delivery, and the role of local therapy for oligoprogression or recurrent disease.
Recommendations were based on a systematic literature review and created using ASTRO guidelines methodology, the organizations said.
